 Company to Move Forward with Application for VenoValve U.S. Pivotal Trial IRVINE, CA ACCESSWIRE January 12, 2021 Hancock Jaffe Laboratories, Inc. NASDAQ:HJLI, a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully concluded its VenoValve Pre-IDE meeting with the U.S. Food and Drug Administration FDA. Topics presented at the meeting included the background and clinical need for the VenoValve, proposed study design, patient monitoring for safety and efficacy, bench testing protocols, and the VenoValve first-in-human results. 